

New Disorder of Serine / Glycine Biosynthesis: Phosphoserine Aminotransferase (PSAT) Deficiency

J Bonham - Claire Hart
Department of Clinical Chemistry
Sheffield Children's Hospital
UK

Case 1

- n Male, second child of healthy, unrelated parents of British origin
- n Well at birth but presented at 9 weeks with frequent, severe, intractable seizures and hypertonia
- n HC had dropped from 9th to <0.4th centile
- n MRI scan showed general atrophy, hypoplastic cerebellar vermis and poor white matter development
- n EEG consistent with multifocal seizure activity



7:56
G

Z: 1.20
P: +0.0 cm
+0.0 cm

1.0
2

F

21.7 L
5.0 P
4.5 F
FRAME: 1/1
ECHO: 1/1
SLICE: 7/14
CONTRAST: GDT PA
KNEE QUAD

Case 1

n Extensive biochemical investigations, only abnormalities were;

-Plasma serine = 51 (60-300) $\mu\text{mol/L}$


-Plasma glycine = 121 (140-420) $\mu\text{mol/L}$

CSF serine = 18 (35-80) $\mu\text{mol/L}$

CSF glycine = <1 (0-10) $\mu\text{mol/L}$

? 3-Phosphoglycerate Dehydrogenase
Deficiency

Serine and Glycine Biosynthesis



- 1 = 3-P-glycerate dehydrogenase
- 2 = 3-P-serine aminotransferase
- 3 = 3-P-serine phosphatase
- 4 = serine hydroxymethyl transferase
- 5 = Glycine cleavage system (NKH)

- n Skin biopsy taken for enzyme assays
- n Treatment with serine (500 mg/kg) and glycine (200 mg/kg) started at 11 weeks, normalising plasma and CSF levels
- n Limited effect on seizures, still having severe seizure episodes requiring PICU admission
- n Became increasingly hypertonic, condition deteriorated, died at 7 months of age

Enzyme Results

- n 3-PGDH = 70 mU /mg protein (controls = 25 ± 2.6)
- n PSAT = 0.9 (controls = 2.0 ± 0.3)
- n PSP = 2.4 (controls = 1.5 ± 0.2)
- n Essentially normal results!

Case 2

- n Sister of Case 1
- n Monitored before birth, fetal growth and development appeared normal
- n Blood sample taken at 2 hrs of age;
Serine = 30 (50-350) $\mu\text{mol/L}$
Glycine = 110 (200-600) $\mu\text{mol/L}$
- n CSF -serine = 5 (35-80) $\mu\text{mol/L}$
-glycine = <1 (0-10) $\mu\text{mol/L}$

- n Supplementation with serine / glycine normalised plasma and CSF levels
- n HC was on 9th centile at birth, increases to 50th-75th by week 18
- n Cranial US at 3 weeks and MRI at 4 months showed no abnormality
- n Experienced an apnoeic episode at 2 weeks, otherwise asymptomatic
- n Developing normally at 3 yrs of age

Enzyme Assay

n Only 3-PGDH measured,

11.6 mU / mg protein (controls = 29.5 ± 2.7 ,
affected = 6.6, 3.7)

*Because these enzyme assays are problematic
the decision was made to use mutational
analysis to investigate further*

Mutational Analysis

- n No mutations in genes for 3-PGDH or 3-PSP
- n Both children compound heterozygotes for mutations in the PSAT gene
- n One frame shift mutation –c.del G107
- n One missense mutation –c.299A>C, p.Asp100Ala

Missense Mutation –pathogenic?

- n Replaces a well conserved aspartate residue with alanine
- n Comparison with the crystal structure of *E. Coli* PSAT indicates a loss of hydrogen bonding between loops when aspartate is replaced by alanine that would be expected to have a deleterious effect on protein folding
- n Expression studies produced a yield of mutant protein 10 fold lower than the wildtype, with a V_{\max} of about 15% of that of the wildtype

PSAT Deficiency

- n Low plasma and CSF serine and glycine
 - n Acquired microcephaly
 - n Severe, intractable seizures
 - n Hypertonia
 - n psychomotor retardation
- n This is a severe neurometabolic disorder with a poor outcome unless treatment is started presymptomatically

Conclusions

- n The first two cases of PSAT deficiency have been identified
- n Clinical features are very similar to 3-PGDH deficiency, except that the microcephaly is acquired not congenital
- n Case 2 confirms the experience of de Koning et al that serine / glycine disorders can be treated very successfully provided treatment begins presymptomatically

Acknowledgments

- n Mark Sharrard, Simon Olpin, Jenny Watkinson, Jim Bonham, - Departments of Clinical Chemistry and Paediatrics, Sheffield Children's Hospital, Sheffield, UK
- n Valerie Race, Gert Matthijs –Centre for Human Genetics, Catholic University of Leuven, Belgium
- n Younes Achouri, Emile Van Schaftingen –Institute of Cellular Pathology, Catholic University of Leuven, Belgium
- n Jaak Jaeken –Department of Paediatrics, University Hospital Gasthuisberg, Leuven, Belgium

- n Special mention goes to Valerie Race for the mutational analysis and Younes Achouri for the enzymology and expression studies